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The epidermal growth factor receptor has multiple
roles in epidermal biology relating to growth, migra-
tion, and, as shown recently, survival of keratinocytes.
In cultured keratinocytes activation of the epidermal
growth factor receptor upregulates expression of Bcl-
xL, an anti-apoptotic Bcl-2 homolog. The functional
contribution of epidermal growth factor receptor-
dependent Bcl-xL expression to keratinocyte survival
is poorly understood. Here we demonstrate that inhibi-
tion of the epidermal growth factor receptor tyrosine
kinase activity with either an epidermal growth factor
receptor antagonistic monoclonal antibody (MoAb
425) or an epidermal growth factor receptor-selective
tyrosine kinase inhibitor (AG 1478) downregulated
Bcl-xL expression in normal human keratinocytes but
had no effect on expression of the pro-apoptotic Bcl-
Apoptosis or programmed cell death represents a mech-anism to dispose of cells that are either not neededby or potentially dangerous to multicellular organisms.Depending on the nature of the signals that initiatethe apoptotic process, active and passive modes of
cell death may be distinguished. Apoptosis induced by the engage-
ment of the cell death receptor Fas as well as radiation-induced,
p53-dependent cell suicide provide examples for active modes of
cell death. By contrast, apoptosis induced by the lack of extracellular
signals may be viewed as a passive or default process. Among the
extracellular signals preventing death by neglect exogenous growth
factors/cytokines and the engagement of adhesion receptors have
recently received widespread attention. Studies by us and others
have implicated activation of the epidermal growth factor receptor
(EGFR) in the survival of normal (Rodeck et al, 1997a, b) and
immortalized (Reinartz et al, 1996; Stoll et al, 1998) keratinocytes.
EGFR ligands also protect colon epithelial cells from death induced
by growth factor withdrawal (Wu et al, 1995; Hague et al, 1997)
and mouse mammary epithelial cells from c-Myc-induced apoptosis
(Amundadottir et al, 1996).
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2 homologs Bad, Bak, and Bax. Bovine pituitary
extract and insulin partially alleviated both, downreg-
ulation of Bcl-xL expression and cell death upon epi-
dermal growth factor receptor inhibition. Forced
expression of Bcl-xL attenuated cell death of immortal-
ized keratinocytes (HaCaT) induced by either forced
suspension (anoikis) or by epidermal growth factor
receptor blockade. These results demonstrate that
epidermal growth factor receptor-dependent signaling
pathways control the balance of pro-apoptotic and
anti-apoptotic Bcl-2 family members expressed in
normal keratinocytes. Inappropriate survival sup-
ported by aberrant signaling through the epidermal
growth factor receptor may contribute to the patho-
genesis of psoriasis and of squamous cell carcinomas.
Keywords: autocrine/cell survival/receptor tyrosine kinase/
skin. J Invest Dermatol 112:443–449, 1999
Susceptibility of cells to apoptosis induced by either active or
passive triggers is controlled in part by intracellular proteins of the
Bcl-2 family. The Bcl-2 protein family is named after its prototype,
the bcl-2 gene, which was first identified as part of a chromosomal
translocation common in human B cell follicular lymphoma
(Bakhshi et al, 1985; Tsujimoto et al, 1985). The family of genes
with structural similarity to bcl-2 is steadily growing. It contains
the bcl-x (Boise et al, 1993), bax (Oltvai et al, 1993), bak (Chittenden
et al, 1995; Farrow et al, 1995; Kiefer et al, 1995), and bad (Yang
et al, 1995) genes among other less well characterized genes. Of
these, the Bcl-2 protein and one Bcl-x isoform (Bcl-xL) are
complementary in function because both can protect cells from
cell death. By contrast, another splice variant of Bcl-x (Bcl-xS), as
well as the Bad, Bak, and Bax proteins have been described to
promote cell death. The mechanism by which Bcl-2 family members
protect cells from apoptosis is not completely understood. The net
presence of pro-apoptotic and anti-apoptotic family members,
however, appears to determine the susceptibility of cells to the
induction of death programs (reviewed in Oltvai and Korsmeyer,
1994).
Activation of growth factor receptors has been shown to affect
the functional state and/or expression patterns of members of the
Bcl-2 family providing direct links between extracellular survival
signals and intracellular mechanisms of survival regulation. For
example, activation of the receptor tyrosine kinase/phosphatidylino-
sitol-3 kinase/Akt pathway in certain cell types leads to phosphoryla-
tion of pro-apoptotic Bad protein (del Peso et al, 1997) followed
by binding of the phosphorylated Bad protein to proteins of the
14-3-3 family. When bound to 14-3-3 Bad is functionally inactive
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(Zha et al, 1996a) and, thus, the balance of pro-apoptotic and anti-
apoptotic regulators of cell death shifts in favor of survival. In
addition to post-translational modification the levels of expression
of Bcl-2 family members are subject to control by exogenous
growth factors. For example, in hemopoietic cells stimulation of
the interleukin-2 receptor not only effects rescue from apoptosis
but also upregulates expression of Bcl-xL (Broome et al, 1995;
Mueller et al, 1996). Our studies have shown that, in human
neonatal keratinocytes, activation of the EGFR by endogenous
autocrine EGFR ligands induces expression of Bcl-xL mRNA
transcripts and protein (Rodeck et al, 1997b).
Several recent studies have addressed the coordinate expression
of different members of the Bcl-2 family in cultured keratinocytes
or normal skin. Consistent with an important role of Bcl-xL in
epidermal biology it is moderately expressed by normal, and
prominently expressed by hyperproliferative and malignant ker-
atinocytes (Wrone-Smith et al, 1995). In contrast, the pro-apoptotic
Bcl-x splice variant, Bcl-xS has not been found to be expressed at
detectable levels in normal skin (Wrone-Smith et al, 1995) or
cultured keratinocytes (Rodeck et al, 1997b). In addition to Bcl-
xL, keratinocytes express the pro-apoptotic Bax (Krajewski et al,
1994; Maruoka et al, 1997), Bak (Krajewski et al, 1996), and Bad
(Kitadai et al, 1998) proteins. It is not known how the net balance
of these and other members of the Bcl-2 family in keratinocytes is
affected by EGFR activation.
In the present study we have examined EGFR-dependent
expression of a panel of Bcl-2 family members including Bcl-xL,
Bad, Bak, and Bax in human neonatal keratinocytes. We describe
specific and cell cycle-independent downregulation of Bcl-xL but
not of any of the pro-apoptotic family members subsequent to
EGFR blockade and prior to the onset of large-scale apoptosis. We
provide evidence that EGFR activation regulated Bcl-xL expression
and survival not only in normal neonatal keratinocytes but also in
immortalized keratinocytes (HaCaT cells). Using HaCaT cells as a
model system for keratinocyte survival we further demonstrate
that forced expression of Bcl-xL alleviated keratinocyte apoptosis
induced by either forced suspension culture or EGFR blockade.
MATERIALS AND METHODS
Cell culture and reagents Human neonatal foreskin keratinocyte cul-
tures were initiated and propagated in MCDB153 complete medium as
described (McNeill and Jensen, 1990). Complete MCDB153 (Sigma, St.
Louis, MO) contained 30 µM Ca21 and was supplemented with amino
acids, ethanolamine, phosphorylethanolamine, hydrocortisone, and insulin
(all from Sigma), recombinant EGF (10 ng per ml, Collaborative Research,
Bedford, MA), and bovine pituitary extract (BPE; prepared from pituitaries
obtained from Pel-Freez, Rogers, WI). Base MCDB153 medium contained
all nonproteinaceous supplements but no EGF, insulin, or BPE. Unless
otherwise stated experiments were performed using MCDB153 base
medium supplemented with insulin only. Antigen specificity and EGFR-
antagonistic properties of MoAb 425 were described previously (Murthy
et al, 1987, 1990; Rodeck et al, 1987, 1990). Tyrphostins AG1478
and 1295 were purchased from Calbiochem (San Diego, CA). Human
recombinant transforming growth factor (TGF) β1 was from R&D Systems
(Minneapolis, MN).
Growth assays Effects of treatments on keratinocyte proliferation were
assessed by counting cells after trypsinization using a hematocytometer and
by determining [3H]TdR uptake as described previously (Vardy et al, 1995).
Cell cycle analysis Cells were incubated in base MCDB153 medium
supplemented with insulin and containing either MoAb 425 (10 µg per ml)
or TGF-β1 (2.5 ng per ml) for 3 d, harvested by trypsinization, and labeled
with propidium iodide [Sigma; 5 µg per ml in phosphate-buffered saline
(PBS), pH 7.4, containing 6 µg per ml RNAse] for 20 min at room
temperature. Samples were analyzed using an EPICS XL flow cytometer
(Coulter, Hialeah, FL).
Immunoblot analysis Cells were harvested as described previously
(Rodeck et al, 1997b). Equal amounts of total cellular protein were
separated on 15% sodium dodecyl sulfate/polyacrylamide gels followed by
immunoblotting as described (Rodeck et al, 1997b) Antibodies to Bak
(Calbiochem), Bax (Calbiochem), and Bad (Transduction Laboratories,
Lexington, KY) were diluted according to the manufacturers’ recommenda-
tion. Rabbit polyclonal anti-Bcl-xL-antibody was provided by Dr. L.H.
Boise (University of Miami, FL), and used at a 1:1000 dilution. Mouse
monoclonal anti-actin antibody was purchased from Amersham Life
Sciences (Arlington Heights, IL).
Apoptosis assays These assays were performed as described previously
(Rodeck et al, 1997a) with minor modifications. DNA nicks and breaks
were detected by terminal deoxy nucleotide-mediated dUTP-biotin nick
end labeling (TUNEL) staining. Briefly, aliquots of µ105 cells were spun
on to glass slides, fixed for 10 min in 4% paraformaldehyde at 4°C and
stored in PBS. Prior to assay cells were permeabilized with 0.5% Triton-
X in PBS. Positive controls were treated with DNAseI as described. After
equilibration in TdT-buffer (Rodeck et al, 1997a) slides were stained with
biotinylated dUTP (Boehringer, Indianapolis, IN) and TdT (Boehringer)
for 60 min at 37°C. After quenching endogenous peroxidase, slides were
stained with streptavidin-horseradish–peroxidase (Vector Labs, Burlingame,
CA), and developed with diaminobenzidine according to the manufacturer’s
recommendations. For counterstaining, light green was used.
For visual analysis of DNA condensation and fragmentation Acridine
Orange (AO) staining was performed. Cells were trypsinized, suspended
in PBS, and placed on to glass slides. Staining was performed by adding
AO solution (Sigma) in PBS to achieve a final concentration of 8.3 µg
per ml followed by coverslipping and examination using a Leitz Orthoplan
fluorescence microscope with epiillumination. Nuclei were considered
apoptotic when they were substantially smaller and hyperchromatic or
irregularly shaped and fragmented when compared with those of control
cells.
Induction of anoikis by forced suspension culture HaCaT cells were
seeded on to 0.9% agarose equilibrated with MCDB153 base medium (at
a density of µ105 cells per ml) in MCDB153 base medium. This treatment
prevented cell attachment by .95% as compared with attachment of
control cells placed on tissue culture-treated plastic plates. At various times
after seeding, cells were harvested and the fraction of cells undergoing
apoptosis determined by TUNEL and AO staining as described above.
Establishment of HaCaT cells with inducible Bcl-xL-expression A
tetracycline-regulatable expression system described previously by us (Jost
et al, 1997) was used to establish HaCaT cells conditionally overexpressing
human Bcl-xL. Control elements of this expression system are contained
in two separate vectors. The tTA vector (ptTA-neo) encodes a transactivator
protein and the episomally maintained tetP vector contains a responsive
operator-promoter element (tetP) that controls gene expression depending
on tTA binding. The tetracycline-regulatable system was established in
HaCaT cells by transfection of the ptTA-neo vector, selection of clones
that expressed a transiently transfected reporter gene (tetP driven luciferase)
in a tightly regulated fashion, and subsequent stable transfection with a
tetP plasmid containing human bcl-xL cDNA (kindly provided by Dr. C.
Thompson, University of Chicago, IL). For the experiments described,
mass cultures HaCaT-Bcl-x and HaCaT-mock were used in parallel,
derived from two different tTA-expressing clones HaCaT-tTA14 and
HaCaT-tTA1 and yielding comparable experimental results. Results shown
were obtained using HaCaT-tTA14-derived cells. Cultures were maintained
in 400 µg per ml G418 (BRL, Gaithersburg, MD), 100 µg per ml
hygromycin B (Boehringer), and 2 µg per ml tetracycline (Sigma); transgene
expression was induced by omitting tetracycline from the culture medium
2 d prior to experimental manipulations.
RESULTS
Effects of EGFR inhibition and exogenous TGF-b1 on
keratinocyte growth and cell cycle distribution Previously,
we have shown that blocking the EGFR in normal human
keratinocytes followed by passaging leads to extensive apoptotic
cell death (Rodeck et al, 1997a). As EGFR blockade also inhibits
keratinocyte proliferation we sought to investigate whether ker-
atinocyte death upon EGFR blockade is a consequence of or
occurs independently of cell cycle arrest. To induce cell cycle arrest
not associated with apoptosis we used exogenous TGF-β1 (2.5 ng
per ml). TGF-β1 has been described earlier to inhibit proliferation
of keratinocytes but does not enhance their susceptibility to
apoptosis (Henseleit et al, 1996; Sachsenmeier et al, 1996). Consistent
with these earlier reports we observed significant (p , 0.01;
Student’s t-test) inhibition of [3H]TdR uptake in normal ker-
atinocytes by treatment with TGF-β1 at 2.5 ng per ml for 3 d. As
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Figure 1. Cell-cycle-independent modulation of anti-(Bcl-xL) but
not pro-apoptotic Bcl-2 family members (Bad, Bak, and Bax) in
keratinocytes by EGFR antagonistic MoAb 425. Early passage neonatal
keratinocyte strains (FK962; FK993; FK996) were maintained for 2–3 d
in either control MCDB153 medium supplemented with insulin or in the
same medium containing either MoAb 425 (10 µg per ml) or TGF-β1
(2.5 ng per ml). Protein expression was determined by western blot analyses
using the appropriate antibodies as described in Materials and Methods.
Treatment of all keratinocyte cultures with MoAb 425 was consistently
associated with reduced expression levels of Bcl-xL, but not Bad, Bak, or
Bax when compared with either control or TGF-β1-treated cultures.
described earlier (Vardy et al, 1995), treatment of keratinocyte
cultures with EGFR antagonistic MoAb 425 at 10 µg per ml for
3 d inhibited [3H]TdR uptake to a similar extent. Furthermore,
both treatments attenuated cell cycle progression in a similar fashion
by reducing the number of cells in S phase accompanied by
accumulation of cells in G0/G1 and G2 phases of the cell cycle as
determined by propidium iodide staining followed by flow cytomet-
ric analysis (not shown). TGF-β1 treatment caused an average
reduction of cells in S phase by 33% 6 14% (mean 6 SD of three
independent experiments using different primary keratinocyte lines)
whereas MoAb 425 treatment was associated with an average
reduction of cells in S phase by 26% 6 9%. Neither treatment
caused apoptosis within the observation period as determined by
morphologic criteria and the absence of cells exhibiting sub-
G1 DNA content. These results demonstrate that, under the
experimental conditions chosen, EGFR inhibition and TGF-β1
treatment have comparable inhibitory effects on proliferation and
cell cycle progression resulting in accumulation of keratinocytes in
G0/G1 and G2.
Expression of members of the Bcl-2-family in keratinocytes
treated with either MoAb 425 or TGF-b1 To address whether
downregulation of Bcl-xL by EGFR inhibition was merely a
consequence of growth inhibition we determined by western blot
analysis expression of pro-apoptotic and anti-apoptotic Bcl-2 family
members in normal keratinocyte cultures growth inhibited by either
MoAb 425 treatment or TGF-β1 treatment (Fig 1). Consistent with
our earlier results EGFR blockade by MoAb 425 consistently led
to downregulation of the anti-apoptotic protein Bcl-xL in all of
nine normal keratinocyte cultures tested; representative results for
three different cultures are shown in Fig 1. In contrast, TGF-β1
treatment did not consistently affect Bcl-xL expression in these
Figure 2. Modulation of Bcl-xL expression in keratinocytes by
EGFR-selective tyrosine kinase inhibitor AG1478. Normal
keratinocytes were maintained for 3 d in base MCDB153 medium
supplemented with insulin and treated with either MoAb 425 (10 µg
per ml), or AG1478 (10 µM) which selectively inhibits phosphorylation
of the EGFR, or control AG1295 (10 µM) which selectively inhibits
PDGFR phosphorylation. (A) Western blot analyses of Bcl-xL and actin
expression as indicated. (B) Densitometric analysis of Bcl-xL signals
normalized to actin controls; significant downregulation of Bcl-xL
expression is evident in normal keratinocytes treated with either tyrphostin
AG1478 or MoAb 425, but not with control AG1295.
keratinocytes. These results demonstrate that expression of Bcl-xL
by keratinocytes is regulated independently of their proliferative
state. In contrast to Bcl-xL, expression of the pro-apoptotic proteins
Bak, Bad, and Bax was not consistently affected by either EGFR
blockade or TGF-β1 treatment in any of the normal keratinocyte
strains tested. Thus, these pro-apoptotic Bcl-2 family members
were expressed in keratinocytes in a cell-cycle-independent and
EGFR-independent manner. Using the EGFR-selective tyrphostin
AG1478 we further determined that blocking the EGFR tyrosine
kinase activity downregulated Bcl-xL expression in normal ker-
atinocytes in a manner similar to MoAb 425 (Fig 2). In contrast,
control AG1295 which at the concentration used (10 µM) has
been described to selectively inhibit the platelet-derived growth
factor (PDGF)R but not the EGFR (Kovalenko et al, 1994; Levitzki
and Gazit, 1995) had no effect on Bcl-xL expression.
Regulation of survival of HaCaT cells by exogenous and
endogenous growth factors We next determined whether
immortalized human keratinocytes (HaCaT) provided an appro-
priate model system for studying keratinocyte apoptosis susceptibil-
ity after EGFR inhibition. HaCaT keratinocytes are derived from
an adult donor, do not senesce in culture, and are non-tumorigenic
in experimental animals (Boukamp et al, 1988). As compared with
normal neonatal keratinocytes induction of apoptosis by passaging
after 3 d of EGFR blockade was less pronounced in HaCaT cells.
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Table I. EGFR-dependent survival of HaCaT cells in
defined mediaa
Condition Nonviable cells (%)
Normal keratinocytes HaCaT
MCDB153 1 BPE 1 Ins 64 6 14 15 6 8
MCDB153 1 Ins 71 6 17 35 6 12
MCDB153 85 6 6 66 6 12
aCells were incubated in the presence of MoAb 425 (10 µg per ml) in different
medium conditions as indicated for 3 d followed by passaging and reseeding in
complete MCDB153 medium. Survival was determined by assessing the fraction of
floating cells within 48 h after passaging. Trypan blue staining confirmed that .90%
of floating cells were not viable. Results (mean 6 SD) of triplicate samples are shown.
For example, when treated with MoAb 425 and passaged, normal
keratinocytes maintained in standard medium conditions (base
medium supplemented with insulin and BPE) undergo extensive
cell death within 24 h (50%–90% of the total population depending
on the strain used) (Rodeck et al, 1997a). In contrast, the same
treatment causes apoptosis in only 15%–25% of HaCaT cells. We
asked the question whether exogenous growth factors contributed
to the relative resistance of HaCaT cells to cell death induction by
EGFR blockade. To address this possibility effects of EGFR
blockade on HaCaT survival and Bcl-xL expression were assessed
using either base medium free of exogenous growth factors,
or base medium supplemented with insulin, or base medium
supplemented with insulin and BPE. When maintained in base
MCDB153 medium only HaCaT cells were as susceptible as normal
keratinocytes in fully supplemented MCDB153 to induction of
cell death by EGFR blockade followed by passaging (Table I). By
contrast, in the presence of insulin and BPE survival of HaCaT
cells upon EGFR blockade and passaging was substantially
improved. The differential susceptibility of HaCaT cells to apoptosis
induction by EGFR blockade in different media conditions correl-
ated with the reduction in Bcl-xL expression levels caused by the
same treatments. For example, in complete MCDB153 medium
only marginal downregulation of Bcl-xL expression by EGFR
blockade was observed whereas marked reduction in Bcl-xL expres-
sion was observed in base medium free of BPE or insulin (Fig 3).
As in normal keratinocytes, EGFR inhibition did not detectably
affect expression of Bak, Bad, and Bax in HaCaT cells (Fig 4). Taken
together, these results demonstrated that HaCaT cells provided a
useful model system in which to investigate EGFR-dependent
keratinocyte survival and regulation of Bcl-xL expression. In addi-
tion, they indicated that Bcl-xL expression in HaCaT cells was
coordinately regulated by both, exogenous growth factors and
endogenous EGFR ligands.
Forced expression of Bcl-xL protects HaCaT cells from
apoptosis To address further the role of Bcl-xL expression in
protecting keratinocytes from cell death we overexpressed Bcl-xL
in HaCaT cells using a tetracycline-controlled inducible expression
system described in detail elsewhere (Jost et al, 1997). In this system,
transgene expression is induced by removal of tetracycline from
the culture medium. As shown in Fig 5, expression of the Bcl-xL
transgene was induced markedly within 2 d after omission of
tetracycline from the culture medium whereas in the presence of
tetracycline Bcl-xL expression was comparable with that observed
in mock-transfected control cells. Downregulation of Bcl-xL expres-
sion in the presence of MoAb 425, however, was less pronounced
in uninduced HaCaT Bcl-x cells (not shown) consistent with low-
level constitutive expression of the transgene. To assess whether
the transduced Bcl-xL was functional we first tested whether it
would protect HaCaT cells from cell death induced by forced
suspension culture. Forced suspension culture is known to induce
apoptosis in HaCaT cells (Frisch and Francis, 1994) accompanied
by downregulation of endogenous Bcl-xL (Rodeck et al, 1997b);
in addition, forced expression of Bcl-2 has already been described
to protect HaCaT cells from apoptosis induced by forced suspension
Figure 3. The effect of EGFR inhibition on Bcl-xL expression by
HaCaT cells is contingent on media conditions. HaCaT cells were
maintained for 3 d in MCDB153 medium supplemented with either
insulin, EGF, and BPE (condition 1), or insulin and EGF (condition 2),
or insulin alone (condition 3), or base medium without exogenous proteins
(condition 4). (A) Western blot analyses of Bcl-xL and actin expression in
the absence (–) or presence (1) of MoAb 425 (10 µg per ml). (B)
Densitometric analysis of signal intensity in MoAb 425-treated as compared
with control cultures normalized to actin controls. The effect of MoAb
425 treatment on Bcl-xL expression of HaCaT cells is most pronounced
in the absence of all exogenous growth factors and barely detectable in
complete MCDB153 medium.
(Frisch and Francis, 1994). We observed that forced overexpression
of Bcl-xL significantly prolonged survival of HaCaT cells in long-
term (up to 6 d) suspension culture when compared with control
cultures maintained in the presence of tetracycline (Table II).
Overexpression of Bcl-xL also inhibited [
3H]TdR uptake of HaCaT
cells by µ30% as compared with control cells expressing physiologic
levels of Bcl-xL (not shown). This result is consistent with reports
showing modest growth inhibition in diverse cell types, including
epithelial cells by the Bcl-xL homolog Bcl-2 (Chiou et al, 1994;
O’Reilly et al, 1996). Taken together, these results suggested that
the transduced Bcl-xL was functionally active.
Next, we examined whether forced expression of Bcl-xL pro-
tected HaCaT cells from cell death induced by EGFR blockade
followed by passaging. We found a marked effect of induced Bcl-
xL expression on HaCaT survival after MoAb 425 treatment
followed by passaging as determined by TUNEL staining within
48 h after passaging (Table III). The fraction of Bcl-xL overexpress-
ing HaCaT cells exhibiting DNA nicking upon MoAb 425 treat-
ment and passaging was significantly reduced when compared with
mock-transfected cultures treated identically. Furthermore, clonal
growth assays revealed significantly improved long-term survival
of HaCaT cells overexpressing Bcl-xL during MoAb 425 treatment
and passaging (Fig 6). The fraction of cells with clonogenic
potential was significantly reduced in MoAb 425 pretreated and
passaged controls (either mock transfected or uninduced cells) and
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Figure 4. MoAb 425 treatment does not affect Bad, Bak, or Bax
expression in HaCaT cells. HaCaT cells were grown for 3 d in base
MCDB153 medium in the presence and absence of either MoAb 425 or
TGF-β1 as indicated and expression levels of Bcl-xL, Bad, Bak, and Bax
determined by western blot analyses.
Figure 5. Regulated expression of a Bcl-xL transgene in HaCaT
cells as determined by western blot analysis. Expression of endogenous
and transduced Bcl-xL proteins in mock-transfected and bcl-x-transfected
HaCaT cells are shown in the presence and absence of tetracycline (1 µg
per ml) as indicated.
Table II. Effect of Bcl-xL overexpression on HaCaT cell
apoptosis induced by forced suspension culturea
Cell line Tetracycline Condition Apoptotic cells (%)
TUNEL AO staining
staining
HaCaT-Mock 1 Plastic ,5 , 5
1 Agarose 98 93
HaCaT-Mock – Plastic ,5 , 5
– Agarose 90 90
HaCaT-Bcl-x 1 Plastic ,5 , 5
1 Agarose 95 84
HaCaT-Bcl-x – Plastic ,5 , 5
– Agarose 24 27
aPrior to assay cells were maintained for 2 d in complete MCDB153 in the
presence (1) or absence (–) of 1 µg per ml tetracycline as indicated. Cells were
trypsinized, aliquoted, and seeded on either plastic or agarose for 6 d using base
MCDB153 medium containing tetracycline as indicated. After 6 d cells were
harvested and aliquots processed for TUNEL and AO staining. The percentage of
apoptotic cells in each sample was determined as described in Materials and Methods.
Results of a representative experiment are shown.
markedly increased in Bcl-xL overexpressing cells when compared
with mock transfected or uninduced cells.
DISCUSSION
The results of this study demonstrate that activation of the EGFR
tyrosine kinase in keratinocytes shifted the balance of pro-apoptotic
Table III. Effect of Bcl-xL overexpression on HaCaT cell
apoptosis induced by EGFR inhibition and passaginga
Cell line Tetracycline Condition Apoptotic cells (%)
HaCaT-Mock 1 Control ,2
1 MoAb 425 18
HaCaT-Mock – Control 3
– MoAb 425 20
HaCaT-Bcl-x 1 Control 3
1 MoAb 425 12
HaCaT-Bcl-x – Control 1
– MoAb 425 1
aCells were seeded on tissue culture-treated plastic using complete MCDB153
medium containing 0.2 µg per ml tetracycline. After 6 h medium was replaced with
base MCDB153 medium containing insulin with (1 µg per ml) or without tetracycline
and either MoAb 15–6A (control) or EGFR antagonistic MoAb 425 at 10 µg per ml
as indicated. After 4 d cells were trypsinized and reseeded on plastic using base
MCDB153 medium. Two days after reseeding cells were harvested and processed
for TUNEL staining to determine the fraction of cells showing DNA-degradation
consistent with apoptotic cell death. Results of a representative experiment are shown.
Figure 6. Effect of Bcl-xL overexpression on long-term survival of
HaCaT cells after EGFR inhibition and passaging. Cells were
trypsinized and seeded on tissue culture-treated plastic using complete
MCDB153 medium containing 0.2 µg per ml tetracycline. After 6 h
medium was replaced with base MCDB153 medium containing insulin
with (1 µg per ml) or without tetracycline and either EGF (control) or
EGFR antagonistic MoAb 425 at 10 µg per ml as indicated. After 4 d
cells were trypsinized and reseeded at clonal density (3 3 103 per cm2) on
plastic using base MCDB153 medium. Two days after reseeding medium
was replaced with complete medium. After 3 wk cells were fixed and
stained with Crystal Violet.
and anti-apoptotic Bcl-2 family members in favor of cell survival.
Our previous studies demonstrated that blocking the EGFR mark-
edly enhances the rate at which cultured keratinocytes die when
subjected to cellular stress such as passaging (Rodeck et al, 1997a).
Importantly, long-term (2–3 d) inhibition of the EGFR was required
before enhanced susceptibility for apoptosis became manifest. This
finding suggested that EGFR activation controlled expression of a
survival regulator expressed by keratinocytes. Consistent with this
idea we observed that inhibition of EGFR activation downregulated
expression of the protector from cell death, Bcl-xL (Rodeck et al,
1997b); this result was recently confirmed (Stoll et al, 1998).
Control of Bcl-xL expression by the EGFR is not unique to
keratinocytes as induction of Bcl-xL expression by EGF and TGF-
α has also been shown in mammary epithelial cells (Nass et al,
1996). As shown here, regulation of survival and Bcl-xL expression
by endogenous EGFR ligands also extended to HaCaT cells, an
immortalized keratinocyte line established from an adult donor
(Boukamp et al, 1988). Interestingly, as compared with normal
keratinocytes, HaCaT cells were less susceptible to apoptosis
induction by EGFR inhibition. Specifically, unknown components
of BPE and, to a lesser extent, insulin partially alleviated induction
of cell death in HaCaT cells by EGFR inhibition and passaging.
Although normal keratinocytes were also less susceptible to apoptosis
induction by EGFR blockade in the presence of BPE (U. Rodeck;
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unpublished observation) the protective effects of BPE or insulin
were more pronounced in HaCaT cells. At present the reason(s)
for this difference is unknown. The anti-apoptotic effect of BPE
and insulin in HaCaT cells also raises the question whether
activation of growth factor receptors other than the EGFR may
contribute to Bcl-xL expression in keratinocytes. A recent report
describing upregulated expression of Bcl-xL in neurons with
increased insulin-like growth factor 1R levels (Singleton et al, 1996)
supports this possibility. Alternatively, insulin may act by increasing
production of endogenous EGFR ligands and, thus, enhance
signaling by the EGFR. In support of this possibility we have
demonstrated earlier that insulin/insulin-like growth factor 1 treat-
ment of keratinocytes induces production of autocrine EGFR
ligands, i.e., TGF-α and amphiregulin, in keratinocytes (Vardy
et al, 1995).
As shown here, downregulation of Bcl-xL expression by EGFR
inhibition was specific and not merely a consequence of unspecific
metabolic changes associated with growth arrest. In support of this
conclusion, treatment of keratinocyte cultures with TGF-β1 did
not consistently affect Bcl-xL expression, although it inhibited
proliferation and cell cycle progression in a manner similar to
EGFR inhibition. Furthermore, inhibition of the EGFR specifically
downregulated expression of the anti-apoptotic Bcl-2 family mem-
ber Bcl-xL, but did not affect expression levels of the pro-apoptotic
family members Bad, Bak, and Bax in normal keratinocytes. These
results are consistent with the hypothesis that the balance between
the anti-apoptotic Bcl-xL and the pro-apoptotic Bad, Bak, and Bax
molecules determines susceptibility of keratinocytes to apoptosis
induction. In support of this model we observed that forced
expression of Bcl-xL markedly attenuated keratinocyte apoptosis
induced by either suspension culture or by EGFR inhibition
followed by passaging. The extent of rescue was variable; however,
we observed partial or complete rescue of MoAb 425-induced cell
death in the majority of the experiments performed. In some
experiments the uninduced Bcl-xL transfectants showed lower
susceptibility to MoAb 425-induced apoptosis when compared
with mock-transfected cells. This result is consistent with our
finding of low level, constitutive expression of the bcl-xL transgene
in the presence of tetracycline. It should be noted that the actual
percentage of apoptotic cells was most probably underrepresented
by the assay methods shown (TUNEL, AO staining) as these
methods only detect cells in a particular stage of the apoptotic
pathway involving nuclear degradation and condensation, respect-
ively. To confirm the results we therefore performed clonogenic
assays in parallel. Consistent with the TUNEL and AO staining
experiments induced overexpression of Bcl-xL led to markedly
enhanced survival in this setting as well.
EGFR-mediated Bcl-xL expression depended on the tyrosine
kinase activity of the receptor because treatment with the EGFR
tyrosine kinase inhibitor AG1478 downregulated Bcl-xL expression
to a similar extent as treatment with EGFR antagonistic MoAb
425. This result extends the recent observation that the EGFR
selective tyrosine kinase inhibitor PD153035 also reduces Bcl-xL
expression in normal and immortalized keratinocytes (Stoll et al,
1998). A similar requirement for tyrosine kinase activity to support
expression of the anti-apoptotic Bcl-2 family members has been
described in various hemopoietic cell systems. For example, tyrosine
kinase activity is required for interleukin-3-dependent expression
of Bcl-2 in hemopoietic cells (Otani et al, 1993), stimulation of
CD3, CD28, or the interleukin-2 receptor are associated with
upregulation of Bcl-2 and/or Bcl-xL in CD4
1 T cells (Mueller
et al, 1996), and Bruton’s tyrosine kinase contributes to the survival
of B cells induced by anti-IGM associated with upregulation of
Bcl-xL (Anderson et al, 1990). Thus, activation of receptor tyrosine
kinases emerges as a common theme in upregulating expression of
anti-apoptotic Bcl-2 family members in various cell types.
Previous studies have shown that receptor tyrosine kinases such
as the insulin-like growth factor 1R also affect pro-apoptotic Bcl-
2 family members such as Bad by post-translational modification
resulting in functional inactivation. This activity rests on receptor-
mediated recruitment to the cell membrane and/or sequential
phosphorylation of phosphatidylinositol-3 kinase, PKB/Akt, and
Bad (Burgering and Coffer, 1995; Datta et al, 1997; del Peso et al,
1997; Franke et al, 1997; Kulik et al, 1997) followed by binding of
Bad to 14-3-3 proteins (Zha et al, 1996a). It is as yet unknown
whether the EGFR uses this mechanism to protect epithelial cells
from apoptosis. This is likely, however, as the EGFR has been
described to stimulate phosphatidylinositol-3 kinase activity upon
activation (Hu et al, 1992; Burgering and Coffer, 1995; Stover et al,
1995). In addition, expression of a mutant EGFR commonly
observed in a variety of malignancies leads to sustained phosphatidyl-
inositol-3 kinase activation (Moscatello et al, 1998). Taken together,
these findings suggest that receptor tyrosine kinases use two
independent mechanisms to inhibit cell death. The first mechanism
rests on phosphorylation cascades and, thus, represents a comparat-
ively rapid response triggered by ligand binding. The second
mechanism leads to upregulation of expression of anti-apoptotic
proteins of the Bcl-2 family and is a comparatively slow process.
This conclusion is based on our finding that downregulation of
Bcl-xL expression on the protein level occurs only 1–2 d after
EGFR inhibition. Overexpression of Bcl-xL has been described in
several epithelial neoplasms including gastric cancer (Kondo et al,
1996), colorectal carcinoma (Krajewska et al, 1996), and lung cancer
(Reeve et al, 1996). Colorectal (Ciardiello et al, 1991) and lung
(Kaseda et al, 1989) carcinoma cells have also been described to
express high levels of EGFR ligands or the EGFR, respectively. It
appears possible that Bcl-xL expression in these tumors may rest,
at least in part, on inappropriate activation of the EGFR either by
overexpression or mutation. In further support of the latter possibil-
ity transfection of human glioblastoma cell line with a truncated,
constitutively active EGFR commonly found in glioma was correl-
ated with the increased expression of Bcl-xL and markedly reduced
apoptosis of the transfected cells in vitro and in vivo (Nagane
et al, 1996).
Our findings confirm and extend recent studies by Stoll et al
(1998) who observed that Bcl-xL overexpression protects HaCaT
cells from cell loss upon EGFR blockade in culture. We report
here that Bcl-xL overexpression protected HaCaT cells also against
apoptosis induced by forced suspension culture (anoikis). Increased
resistance to anoikis has been recently described for keratinocytes
derived from psoriatic plaques (Wrone-Smith et al, 1997). In
addition, overexpression of the EGFR, its ligands TGF-α (Gottlieb
et al, 1988; Elder et al, 1989; Cook et al, 1992) and amphiregulin
(Cook et al, 1992), and Bcl-xL (Wrone-Smith et al, 1995) is
frequently observed in psoriatic lesions. Our results suggest the
conclusion that inappropriate EGFR signaling contributes to Bcl-xL
overexpression and may protect psoriatic keratinocytes in suprabasal
layers of the epidermis against anoikis. As discussed above, deregu-
lated EGFR dependent Bcl-xL expression may also support inappro-
priate survival of malignant epithelial cells. Increasing susceptibility
of cancer cells to apoptosis by inhibiting the EGFR itself or signal
transduction mechanisms and effectors relevant to Bcl-xL expression
provides potentially worthwhile therapeutic targets.
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